Personalized dosing OnDosis specializes in flexible, individualized oral dosing delivered as pellets, granules, mini tablets or powders, presenting a strong value proposition for pharma and biotech partners pursuing precision medicine, dose customization, and patient-specific therapies.

Strategic collaborations Recent and ongoing partnerships with Revio Therapeutics, Diamond Therapeutics, and Camallergy indicate a collaborative growth strategy; these relationships create warm introductions to potential customers seeking drug-device combination solutions and integrated patient dosing platforms.

Therapeutic expansion Focused on high-need areas such as ADHD, food allergies, pain management, and immunosuppression for organ transplants, there are clear market entry points for clinical development programs and co-development deals targeting underserved patient populations.

Regulatory and awards credibility Recognition like UX Design Awards and a spin-out heritage from AstraZeneca enhance credibility for stringent regulatory environments, assisting early conversations with QA, compliance, and regulatory affairs teams.

Early-stage growth signals With sub-$1M revenue and $15M in funding, OnDosis is at a pre-Series A/B growth phase, presenting opportunities for strategic investors, grant-supported projects, and partnerships with mid-sized biopharma seeking to augment their personalized dosing capabilities.